We evaluated the performance of 5 different platforms for detecting EGFR T790M in cfDNA and the subsequent treatment responses in EGFR mutation-positive NSCLC patients with acquired TKI resistance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.